AGC Biologics Expands Cell Therapy Development Operations to Asia to Serve Growing Market Need
This new site precedes the opening of a new AGC Biologics Yokohama manufacturing facility on schedule to be operational in 2027 with pre-clinical through commercial services for mammalian-based protein biologics, cell therapies, and messenger RNA.
The Yokohama location will provide process transfer and manufacturing services for pre-clinical and clinical trials to serve an expanding global cell therapy market. Its core technologies include induced pluripotent stem cells, mesenchymal stem cells, hematopoietic stem cells, and CAR-T cell therapies. AGC Biologics Cell and Gene Technology Center of Excellence in Milan, with its nine product approvals by the EMA and FDA, hundreds of batches manufactured, and 30-year track record, will support and enable the successful ramp up of operation in the new Yokohama site.
'In a cell and gene therapy market of high volatility and witnessing consolidation of CDMOs, AGC Biologics is among the few experiencing significant growth and success. We are now building on this success to complete the vision of having a truly global offering,' said Luca Alberici, Executive Vice President of Global Cell and Gene Technologies at AGC Biologics. 'Now Asian developers can benefit from having a local supply within one of the best global infrastructures on the market for cell therapy. Moreover, customers can continue to leverage the offering of viral vector central supply in our Milan facility, which supplies around a third of the ex vivo gene therapy product approved for commercialization. AGC Biologics, through its proprietary ProntoLVV and BravoAAV platforms, aims to offer viral vectors at a sustainable cost for its clients targeting less than 1,000€ per CAR-T patient.'
'Our team of friendly experts in Milan have a strong reputation for collaboration and working side-by-side with customers to achieve clinical, late-phase, and commercial successes,' said Jun Takami, Senior Vice President and General Manager, Japan Region and Yokohama Facility. 'As part of this next major phase for cell therapy in the region, our Yokohama team is ready to support partners in accelerating drug development timelines while maintaining the highest quality standards in the industry."
AGC Biologics is a part of AGC Inc.'s Life Science Company. The Life Science company operates over 10 facilities worldwide focused on biopharmaceuticals, advanced therapies, small molecule active pharmaceutical ingredients, and agrochemicals. The AGC Inc. Yokohama Technical Center, built in 2020, is dedicated to advancing AGC Inc.'s research and development capabilities in materials science, chemical processes, and biotechnology.
Please visit www.agcbio.com to learn more about AGC Biologics' global network of services for protein biologics and cell and gene therapies.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, to provide friendly and expert services. We provide world-class development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with locations in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba and Yokohama, Japan. We currently employ more than 2,600 Team Members worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
MetLife Declares Third Quarter 2025 Preferred Stock Dividends
NEW YORK, August 15, 2025--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $0.35263005 per share on the company's floating rate non-cumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE: MET PRA). Semi-annual dividend of $29.375 per share on the company's 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarterly dividend of $351.5625 per share on the company's 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest in a share of the preferred stock, holders of which will receive $0.3515625 per depositary share (NYSE: MET PRE). Quarterly dividend of $296.875 per share on the company's 4.75% non-cumulative preferred stock, Series F, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest in a share of the preferred stock, holders of which will receive $0.296875 per depositary share (NYSE: MET PRF). Semi-annual dividend of $19.250 per share on the company's 3.850% fixed rate reset non-cumulative preferred stock, Series G, with a liquidation preference of $1,000 per share. The above dividends will be payable Sept. 15, 2025, to shareholders of record as of Friday, Aug. 29, 2025, due to the record date occurring on Sunday, Aug. 31, 2025. About MetLife MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit Forward-Looking Statements The forward-looking statements in this news release, using words such as "will," are based on assumptions and expectations that involve risks and uncertainties, including the "Risk Factors" MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife's future results could differ, and it does not undertake any obligation to publicly correct or update any of these statements. View source version on Contacts For Media: Jane For Investors: John Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
18 minutes ago
- Business Wire
MetLife Declares Third Quarter 2025 Preferred Stock Dividends
NEW YORK--(BUSINESS WIRE)--MetLife, Inc. (NYSE: MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $0.35263005 per share on the company's floating rate non-cumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE: MET PRA). Semi-annual dividend of $29.375 per share on the company's 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarterly dividend of $351.5625 per share on the company's 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest in a share of the preferred stock, holders of which will receive $0.3515625 per depositary share (NYSE: MET PRE). Quarterly dividend of $296.875 per share on the company's 4.75% non-cumulative preferred stock, Series F, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest in a share of the preferred stock, holders of which will receive $0.296875 per depositary share (NYSE: MET PRF). Semi-annual dividend of $19.250 per share on the company's 3.850% fixed rate reset non-cumulative preferred stock, Series G, with a liquidation preference of $1,000 per share. The above dividends will be payable Sept. 15, 2025, to shareholders of record as of Friday, Aug. 29, 2025, due to the record date occurring on Sunday, Aug. 31, 2025. About MetLife MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates ('MetLife'), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help individual and institutional customers build a more confident future. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Asia, Latin America, Europe and the Middle East. For more information, visit Forward-Looking Statements The forward-looking statements in this news release, using words such as 'will,' are based on assumptions and expectations that involve risks and uncertainties, including the 'Risk Factors' MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife's future results could differ, and it does not undertake any obligation to publicly correct or update any of these statements.
Yahoo
40 minutes ago
- Yahoo
Enhanced VisualVault Human Resources Employee Content Management Features Critical to Maintaining Compliance
TEMPE, Ariz., August 15, 2025--(BUSINESS WIRE)--VisualVault, a leader in digital information management, has introduced the most recent version of its employee content management solution for Human Resources departments. This update of the VisualVault HR offering includes an enhanced set of compliance features that are applicable to businesses of all sizes and across industries, but particularly well-suited to organizations in highly-regulated industries. While the enhanced offering is well-suited to serve the needs of all sizes of businesses and industries, it is particularly valuable for mid-sized to small businesses in manufacturing, construction, healthcare, transportation, and other highly regulated industries. For these smaller organizations that do not employ an HRIS system but face demanding compliance requirements, the newest VisualVault solution delivers a set of features that address the ever-increasing retention and compliance mandates associated with Human Resources documentation. VisualVault CEO Avner Schneur says, "HR organizations bear the burden of meeting a volume of complex records retention requirements. And, without the proper technology assets, maintaining compliance can be a challenge of great proportion." Schneur goes on to say, "Our current document management solution provides the complete suite of features required to efficiently keep HR records organized, distributed as needed and retained as required." One example of regulations that create complexity is OSHA (Occupational Safety & Health Administration) regulations, which are prominent in highly regulated industries. Some OSHA regulations mandate the retention of documents for five years, while others OSHA regulations mandate that employee health records are maintained for thirty years. The complexity, breadth, and details that define retention across government and industry bodies demand an advanced technology solution. The newest VisualVault HR offering delivers proper organization and retention of these records, custom alerts when a relevant retention or renewal date associated with critical records is met and other functions that deliver successful stewardship throughout the life of critical HR records. VisualVault delivers a full breadth of advanced digital process automation (DPA), business process management (BPM), enterprise content management (ECM) and content services platform (CSP) solutions in a range of vertical markets and horizontal applications such as Human Resources and Finance. About VisualVault VisualVault is a company and AI-enabled, cloud-based enterprise content management (ECM) platform that is low-code, highly-configurable and architected to process high-volume, high-value data and transactions. VisualVault structures unstructured data via its intelligent forms, puts that data to work with workflow automation, displays data and insights with its advanced analytics suite and delivers advanced document management functionality. These capabilities collectively make VisualVault well-suited to rapidly and efficiently lead organizations through digital transformation processes. View source version on Contacts Mike Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
